Replies to post #211289 on Biotech Values

[DewDiligence]

CHRS/MNTA/AMGN/etc—If ABBV's '135 patent is invalidated, it will help all of the companies seeking to commercialize a Humira FoB for the US market—not just CHRS (as the Maxim analyst alleges).

This is a really bad hack job by a sell-side analyst!

ABBV's '135 patent covers biweekly subcutaneous dosing of Humira for RA.

[DewDiligence]

CHRS BLA for Humira FoB delayed to 1H18 due to fill/finish problems:

https://www.sec.gov/Archives/edgar/data/1512762/000119312517213200/d389037d8k.htm